Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Laparoscopic Hepatectomy

Inclusion criteria

• Age between 18 and 75 years, any gender;
• American Society of Anesthesiologists (ASA) score of I or II;
• BMI between 18 kg/m² and 30 kg/m²;
• Patients scheduled for laparoscopic liver resection under general anesthesia, with surgery lasting less than 6 hours;
• Surgical incision less than 10 cm;
• Able to understand pain intensity assessment methods.

Participants understand the purpose and procedures of this study, voluntarily participate, and sign a written informed consent form.

Exclusion criteria

• Patients allergic to opioids, flurbiprofen ester, or any other ingredients in the investigational drugs.
• Patients expected to use continuous epidural analgesia or local block analgesia during the treatment period.
• Patients with a history of gastrointestinal ulcers or bleeding who need treatment.
• Patients undergoing emergency surgery or trauma.
• Patients whose surgery needs to be converted to open abdominal surgery.
• Patients unwilling to use patient-controlled intravenous analgesia (PCIA).
• Patients with a history of upper abdominal surgery.
• Patients expected to require postoperative continued intubation.
• Patients needing postoperative admission to the ICU.
• Patients with any of the following disease history or evidence before screening:
• Severe cardiovascular or pulmonary diseases (myocardial infarction, heart failure, or respiratory failure).
• Neurological or psychiatric history: brain injury, intracranial hypertension, schizophrenia, mania, etc., judged by the investigator as not suitable for the study.
• History of digestive diseases: intestinal obstruction or other digestive system diseases that may cause nausea or vomiting as judged by the investigator; accompanied by other severe digestive tract issues affecting digestion (e.g., severe constipation, duodenal stasis syndrome, etc.), or other digestive diseases evaluated by the investigator as unsuitable for the study.
• Patients with obvious chronic dizziness or diagnosed vestibular function disorders (other than motion sickness), including but not limited to peripheral vestibular syndrome or central vestibular syndrome.
• Patients who received neoadjuvant treatment before surgery.
• Patients who experienced nausea, retching, or vomiting within 24 hours before anesthesia induction (excluding bowel prep-related cases).
• Known allergy or contraindication to other anesthetics or antiemetics that may be used during the trial.
• Patients who used drugs with unclear half-lives that have analgesic or antiemetic effects within 14 days before randomization, or whose last use was less than 5 half-lives or the drug's effective duration (whichever is longer), including but not limited to opioids, non-opioid analgesics, antiemetics (or drugs with antiemetic effects), sedatives, anesthetics, corticosteroids, and other similar drugs.
• Patients needing dialysis or who have alcoholism during treatment.
• Pregnant or breastfeeding women, or those planning pregnancy during the study period or within 3 months after study completion.
• Subjects the investigator believes have any other factor making them unsuitable for this clinical study.